Aleman-Mateo H, Carreon VR, Macias L, Astiazaran-Garcia H, Gallegos-Aguilar AC, Enriquez JR
GLP-1 medications have helped many individuals achieve results that previously felt out of reach, but they work best when integrated into a comprehensive strategy focused on nutrition, exercise, metabolic health, and long-term sustainability
SABOURET, is now available as a preprint in Archives of Medical Science (AMS) The problem GLP-1 receptor agonists and SGLT2 inhibitors have become central components of cardiovascular, renal, and metabolic care
The dataset included information on 41 million lives, with prescription and mortality data spanning from 2015 to January 1, 2025
KLOW suits researchers running multi-pathway recovery protocols who want the convenience of a single vial